Purpose: The increasing prevalence of distant metastases from non-small cell lung cancer (NSCLC) indicates an urgent need for novel therapeutic modalities. Brain metastasis is particularly common in NSCLC, with severe adverse effects on clinical prognosis. Although the molecular heterogeneity of NSCLC and availability of various targeted agents suggest personalized therapeutic approaches for such brain metastases, further development of appropriate preclinical models is needed to validate the strategies.
Introduction
Despite efforts to develop novel personalized therapeutic strategies and predictive biomarkers, non-small cell lung cancer (NSCLC) remains the leading cause of cancer-related mortality (1) . Recent successful application of EGFR (2) and anaplastic lymphoma kinase (ALK)/met proto-oncogene (MET; ref.
3) tyrosine kinase inhibitors to NSCLCs highlights the importance of genotype-based individualized targeted therapies. However, due to the extensive molecular and functional heterogeneity of NSCLCs, genomic abnormalities often are not the ideal therapeutic efficacy predictors for various targeted agents. Moreover, new drugs targeting deregulated signaling pathways rather than specifically altered oncogenes have been increasingly developed.
The major cause of death from NSCLC is metastases that are resistant to conventional therapies. In particular, brain metastases are detected in 10% to 25% of patients with NSCLC at initial diagnosis, and 40% to 50% of patients with lung cancer develop brain metastases during their clinical course (4, 5) . The standard treatments for NSCLC brain metastases, which include surgical resection, radiotherapy, chemotherapy, or a combination of these, are rarely curative and often result in severe neurologic morbidities (6) . Nevertheless, there is a clinically urgent need for improved therapeutic approaches to treat patients with NSCLC brain metastasis. Unfortunately, clinical activity data on targeted agents for the treatment of NSCLC brain metastases remain sparse.
Previous evidence suggests that patient-derived xenografts (PDX) may be a more clinically relevant preclinical model that would increase the success of novel drug identification compared with cell line-derived xenografts (7, 8) . These PDX-based preclinical systems accurately represent the molecular, genetic, and histopathologic heterogeneity of the original tumors through serial passaging in mice (9, 10) . The conserved genetic diversity within these models and molecular/functional similarity between PDXs and their corresponding parental tumors provide the opportunities to further develop and validate personalized approaches for the treatment of heterogeneous NSCLCs with or without specific genomic abnormalities.
Although several NSCLC PDX panels have demonstrated a high correlation between preclinical and clinical results (7, 10, 11) , they are mainly established from the primary tumors of treatment-na€ ve patients with NSCLC and thereby fail to recapitulate the patient population with metastatic/treatment refractory diseases. Moreover, previous laboratory techniques often yielded relatively low engraftment rates of surgical specimens in immunedeficient mice (20%-40%; refs. 7, 10, 11) . Recently, surgical resection has become one of the viable therapeutic options for patients with NSCLC brain metastasis with neurologic and/or lifethreatening symptoms (12) . Because PDX establishment rates are much higher in biologically aggressive tumors (7, 10, 11) , surgically removed NSCLC brain metastases instead of early-stage primary lung specimens might extend the application of PDX models to a wider range of patients and meet more urgent clinical needs.
Herein, we established NSCLC PDX models using primary and brain metastasis specimens to compare their in vivo engraftment rates and potentials as preclinical drug-screening platforms. We demonstrated that surgically removed brain metastases could be excellent sources for the establishment of an NSCLC preclinical platform that closely mimics the more aggressive clinical situation and can be used for in vitro personalized drug screening.
Materials and Methods

NSCLC surgical samples and clinicopathologic parameters
This study was approved by the Samsung Medical Center (Seoul, Korea) Institutional Review Boards (IRB) and all participants provided written informed consent (No. 2010-04-004). Surgical specimens and clinical records were obtained from 98 patients with NSCLC who underwent surgical removal of the primary tumors (n ¼ 64) or brain metastases (n ¼ 34) at our institute from 2008 to 2012. Tumors were classified as NSCLC based on the World Health Organization (WHO) criteria upon examination by licensed pathologists. Synchronous brain metastasis was defined as brain metastatic lesions diagnosed before or within 3 months of the primary NSCLC diagnosis. All others were considered metachronous brain metastasis. Patients were categorized as never smokers (<100 cigarettes in their lifetime) or ever smokers (!100 cigarettes in their lifetime) according to their smoking status. NSCLC histologic subtypes and stages were classified by the pathologists according to the WHO criteria (13) and the American Joint Committee on Cancer staging system (7th edition; ref. 14) , respectively. The presence of a solid growth pattern (>10% solid sheets of tumor without the formation of acini, papillae or micropapillae, or sheets or nests of tumor areas with fibrous tissue) in the adenocarcinoma subtype was determined because this pattern is an indicator of poor prognosis (15) (16) (17) . Surgical specimens were divided into three portions for implantation into immune-deficient mice, DNA/RNA extraction, and pathologic assessment within 6 hours after surgery.
PDX model establishment
Animal experiments were conducted in accordance with the Institute for Laboratory Animal Research Guide for the Care and Use of Laboratory Animals and following protocols approved by the IRB at the Samsung Medical Center (Seoul, Korea). Athymic nude and NOG (IL2 receptor g-chain truncated NOD/SCID) mice were utilized (Orient Bio). For the transplantation, 6-to 8-weekold female mice were anesthetized with 100 mg/kg ketamine and 10 mg/kg xylazine. Primary NSCLC samples (n ¼ 64) minced into approximately 1 mm 3 fragments in high-concentration Matrigel Basement Membrane Matrix (BD Biosciences) were directly implanted into the subcutaneous space or subrenal capsule (n ¼ 4-5 for each tumor sample). NSCLC brain metastasis specimens (n ¼ 34) were implanted subcutaneously in high-concentration Matrigel Basement Membrane Matrigel after mincing or stereotactically injected into the brains (2 mm left and 1 mm anterior to the bregma, 2 mm deep from the dura) after dissociation into single cells according to previously published protocols [refs. 18, 19; 2.5 Â 10 4 -1.0 Â 10 5 cells in 10 mL Hank's Balanced Salt Solution (HBSS; Life Technologies), n ¼ 4-5 for each tumor sample]. Mice were maintained and observed for 6 months for the development of xenograft tumor. For subcutaneous and subrenal capsule implantation, xenograft tumor engraftment was defined as a palpable mass of >1 mm in diameter and pathologic confirmation. For intracranial injection, body weight loss of >20% and pathologic confirmation were assessed as successful PDX model establishment. The origin of each xenograft was validated by short tandem repeat DNA fingerprinting. The PDX tumors were harvested and divided into three portions for the generation of the second in vivo passage xenograft tumors, DNA/RNA extraction, and histopathologic examination.
Translational Relevance
The incidence of metastatic brain tumors is increasing due to the development of novel therapeutic modalities controlling primary cancers effectively. Especially, brain metastasis develops early in non-small cell lung cancer (NSCLC); brain metastases are found in 10% to 25% of patients with NSCLC at initial diagnosis. Although standard treatments for NSCLC brain metastases are rarely curative, resulting in severe neurologic morbidities, very few pathophysiologic studies were performed on NSCLC brain metastasis, nor are there appropriate preclinical models with which to study. In this study, we have demonstrated that patient-derived xenografts (PDX) developed from brain metastasis would increase the success of identifying active drugs for the individual patient. To the best of our knowledge, this is the first report demonstrating that PDXs from NSCLC brain metastases would represent heterogeneous advanced NSCLC population and that they have several merits as a valuable translational research platform to elucidate key molecular and genetic mechanisms for an individual tailored therapeutic approach to each patient.
Histology and IHC
Formalin-fixed paraffin-embedded (FFPE) samples were processed according to conventional experimental protocols. Serial 5-mm-thick sections from each FFPE block were processed for hematoxylin and eosin (H&E) staining and were examined by a specialized pathologist. IHC was performed as previously described (20) using the following primary antibodies: thyroid transcription factor-1 (TTF-1; Abcam; ab40880, 1:1,000), Napsin-A (Abcam; ab133249, 1:250), and p63 (Abcam; ab53039, 1:200).
Genomic characterization
Array comparative genomic hybridization (aCGH) was performed using Agilent Human Whole Genome CGH 8 Â 60 K microarray (Agilent Technologies, Inc.). Labeling and hybridization were performed according to the manufacturer's instructions. Briefly, 0.5 mg of test or reference genomic DNA (gDNA) was digested with AluI and RsaI (Promega) and purified using the QIAprep Spin Miniprep Kit (QIAGEN). DNA samples were labeled by random priming with either Cy3-dUTP or Cy5-dUTP using the Agilent Genomic DNA Labeling Kit PLUS (Agilent Technologies, Inc.). Individually labeled test and reference samples were combined and concentrated using Amicon Ultra-0.5 centrifugal filters (Millipore). After denaturing the probe and preannealing with human Cot-1 DNA, samples were hybridized at 65 C and 20-rpm rotation for 24 hours in a DNA Microarray Hybridization Oven (Agilent Technologies, Inc.). Slides were scanned on an Agilent DNA microarray scanner. Data were obtained using Agilent Feature Extraction Software 9 and analyzed with Agilent CGH Analytics Version 6.5 software, using the ADM-2 statistical algorithms with 6.0 sensitivity thresholds.
For gene mutational analysis, Ion Torrent sequencing was performed following the Ion Torrent protocol (Life Technologies). gDNA (10 ng) was amplified by single-tube, multiplex PCR using the Ion AmpliSeq Cancer Primer Pool (Life Technologies). Template DNA and unincorporated primers were removed from the amplicons by binding to Agencourt AMPure XP Reagent (Beckman Coulter). Amplicons were treated with FuPa reagent to partially digest primer sequences and phosphorylate the amplicons. A library was prepared with reagents from the Ion Plus Fragment Library Kit (Life Technologies). Amplicons were ligated to Ion-compatible adapters. The ligated DNA underwent nicktranslation and amplification to complete the link between adapters and amplicons and to generate sufficient materials for downstream template preparation. The concentration and size were determined using an Agilent BioAnalyzer DNA High-Sensitivity DNA Chip (Agilent Technologies, Inc.). Sample emulsion PCR, emulsion breaking, and enrichment were performed using the Ion OneTouch Template Kit (Life Technologies). Each sample was prepared for sequencing using the Ion Sequencing Kit (Life Technologies). The final template-positive Ion sphere particles were loaded onto an Ion 314 chip and sequenced on the Ion Personal Genome Machine Sequencer (Life Technologies) for 65 cycles.
Primary in vitro short-term culture
Xenograft tumor specimens were dissociated in to single cells according to previously published protocols (18, 19) . Dissociated NSCLC cells were cultured in neurobasal media-A supplemented with N2 (Â1/2; Life technologies), B27 (Â1/2; GIBCO), basic fibroblast growth factor (bFGF; 25 ng/mL; R&D Systems), EGF (25 ng/mL; R&D Systems), neuregulin 1 (NRG; 10 ng/mL; R&D Systems), and insulin-like growth factor 1 (IGF1; 100 ng/mL; R&D Systems). Growth factors were supplemented every 3 days. As spheres appeared in the suspension culture, they were dissociated using StemPro Accutase (Life Technologies) and expanded by reseeding in the aforementioned suspension culture medium.
In vivo systemic metastasis assay
To examine the in vivo metastatic capacity of primarily cultured NSCLC brain metastasis PDX cells, 1 Â 10 4 dissociated cells in 0.1 mL HBSS were injected into the left ventricle of 6-week-old athymic nude mice. The animals' body weights were measured every day and autopsy was conducted when >25% weight loss was reached. The brain, lungs, lower leg bones, adrenal glands, and abnormal organs were examined by H&E staining.
In vitro drug sensitivity assay
Primarily cultured NSCLC brain metastasis PDX cells in the serum-free sphere culture condition were seeded in 384-well plates at 500 cells per well. Two hours after plating, cells were treated with a drug library in 3-fold and 10-point serial dilution series (n ¼ 3 for each condition). After 6 days of incubation at 37 C in a 5% CO 2 humidified incubator, cell viability was analyzed using an adenosine triphosphate monitoring system based on firefly luciferase (ATPlite 1step; PerkinElmer). The drug library was composed of 20 targeted agents that were included in the clinical guideline or current clinical trial for the treatment of NSCLC (gefitinib, erlotinib, lapatinib, afatinib, tivantinib, foretinib, crizotinib, selumetinib, temsirolimus, everolimus, cabozantinib, vandetanib, sunitinib, sorafenib, dovitinib, vemurafenib, BKM 120, pazopanib, nintedanib, and DAPT; all purchased from Selleckchem). The drugs were stored and diluted according to the manufacturers' instructions. Test concentrations for each drug were empirically derived to produce a clinically relevant spectrum of drug activity. IC 50 values were calculated as an average of triplicated experiments using the Sþ Chip Analyzer (Samsung Electro-Mechanics Company, Ltd.; ref. 21) .
For signal transduction assays under treatment with targeted agents, primarily cultured NSCLC brain metastasis PDX cells were maintained overnight in serum-free sphere culture condition without growth factors, incubated for 1 hour with each inhibitor, and pulsed with original culture medium supplemented with bFGF/EGF/NRG/IGF for 15 minutes. For Western blot analysis, cells were lysed in RIPA lysis buffer supplemented with 1Â phosphatase inhibitors (PhosStop; Roche Diagnostics) and a 1Â protease inhibitor cocktail (Complete Mini; Roche Diagnostics). After centrifugation at 10,000 g for 5 minutes, the supernatant was harvested. Protein concentration was determined using a bicinchoninic acid protein assay kit (Thermo). Equal amounts of protein were subjected to SDS-PAGE and transferred to polyvinylidene difluoride membranes (Whatman), which were blocked in 5% skim milk or BSA for 1 hour at room temperature, incubated with the indicated primary antibodies overnight, and then blotted with the appropriate secondary antibodies. Antibodies against phospho-EGFR (Tyr1068), phospho-MET (Tyr1234/ 1235), phospho-AKT (Ser473), phospho-mTOR (Ser2448), phospho-p70S6K (Thr389), phospho-p44/42 MAPK (Erk1/2) (Thr202/Tyr204), p44/42 MAPK (Erk1/2; Cell Signaling Technology), EGFR, MET, AKT, mTOR, p70S6K, and GAPDH (Santa Cruz Biotechnology) were used.
Statistical analysis
The in vivo tumor take rates were compared by the c 2 test. The Fisher exact test was used to determine the association of clinicopathologic features with successful PDX engraftment. All P values were two-sided, and a P < 0.05 was considered statistically significant. All data analyses were performed with SPSS statistical software (Statistical Product and Services Solutions, version 19.0).
Results
Establishment of NSCLC PDX models and parameters related to in vivo tumor formation
The overall clinicopathologic characteristics of all NSCLC cases (n ¼ 98) are presented in Supplementary Table S1 . Although the primary NSCLC group (n ¼ 64) had larger tumors than the brain metastasis group (n ¼ 34, P < 0.001), age, sex, smoking status, histologic subtype, tumor differentiation, neoadjuvant chemotreatment history, and genetic abnormality status were similar in the two groups. The establishment of a PDX model was monitored by body weight change (for intracranial injection) and palpable mass formation (for subcutaneous and subrenal capsule implantation) and defined as viable tumor formation (>20% body weight loss or >1 mm 3 mass) with pathologic confirmation in at least one transplanted mouse. The overall in vivo tumor take rate was 41% (40/98). Interestingly, the engraftment rate of NSCLC brain metastases (25/34, 74%) was significantly higher than that of primary NSCLCs (15/64, 23%) in the first generation of Figure 1 . Successful establishment rates of NSCLC patient-derived xenograft models. A, in vivo tumor take rates were compared according to the sources of NSCLC surgical samples. B, overall survival of patients with NSCLC brain metastases whose surgical samples had in vivo tumorigenic potential (n ¼ 25), or not (n ¼ 9), was compared. C, histologic and immunohistochemical comparison of patient and corresponding xenograft tumors. ADC, adenocarcinoma. transplantation ( Fig. 1A , P < 0.001). In vivo passagability and time to xenograft tumor formation of each NSCLC PDX model were summarized in Supplementary Table S2 . In 30 of the 40 PDX models (75%), in vivo passagability (>2) was confirmed.
To determine the clinicopathologic parameters related to successful in vivo tumor formation, PDX model establishment rates were calculated and compared according to various patient characteristics (Supplementary Tables S3 and S4 for patients with primary and brain metastatic NSCLC, respectively). The primary (Table 1 ) and brain metastatic (Table 2 ) NSCLC cases were separately analyzed, because the two groups showed significantly different PDX model establishment rates (Fig. 1A) . In the primary NSCLC group, squamous cell carcinoma (SCC) histologic subtype, concurrent distant metastasis, progressed overall tumor stage, presence of the solid component in adenocarcinoma histologic subtype, and wild-type EGFR genotype were significantly associated with successful PDX model establishment (Table 1 and  Supplementary Table S3) . Age, sex, smoking status, tumor size, pathologic tumor-node (TN) stage, implanted mouse strain, implantation route, differentiation of adenocarcinoma subtype, neoadjuvant chemotherapy, KRAS genotype, and ALK genotype showed no significant correlation with in vivo tumor take rate (Table 1) . In contrast, in the NSCLC brain metastasis group, no clinicopathologic features led to significant differences in the PDX model establishment result (Table 2 and Supplementary Table  S4 ). Previously, in vivo tumorigenic potential of patient-derived cancer cells was correlated with worse clinical outcomes of patients (18) . The significant relationship was also observed in the NSCLC brain metastasis samples (Fig. 1B, P ¼ 0.008) , although follow-up time was not different (P ¼ 0.076).
Preservation of the parental NSCLCs' biologic characteristics in PDX models
The utility of PDX models as a model system for human NSCLCs depends on the precise reflection of the parental tumors' pathologic and molecular characteristics. Parental NSCLCs and corresponding xenograft tumors (n ¼ 15 and 25 for primary and brain metastatic NSCLCs, respectively) were determined whether the engraftment of NSCLC tissues in immunodeficient mice maintained the key features of the parental tumors. Pathologic comparison revealed a high degree of similarity in the subtypespecific morphologic features and differentiation status between the xenografts and corresponding parental tumors ( Fig. 1C and Supplementary Fig. S1 ). Moreover, the preferential expression of NSCLC histologic subtype-specific markers such as TTF-1, Napsin A (for adenocarcinoma), and p63 (for SCC) was reproduced in the xenograft tumors (Fig. 1C) . When xenograft tumors were serially transplanted into immunodeficient mice, the parental tumor characteristics were maintained at least until the third in vivo passage (data not shown). Genomic similarities (gene copynumber alterations and mutations) between parental and corresponding xenograft tumors were also confirmed by aCGH and Ion AmpliSeq Cancer Panel sequencing results (data not shown).
Application of NSCLC brain metastasis PDX models to personalized anticancer agent screening PDX model establishment experiments demonstrated that in vivo tumor take rate was significantly higher when surgical samples from NSCLC brain metastases were utilized (74% vs. 23%, Fig. 1A) . Moreover, PDX models could be consistently generated by NSCLC brain metastasis samples regardless of varying NSCLC clinicopathologic characteristics (Table 2) . Similarly, in vitro primary culture of NSCLC cells from PDX tumors in serumfree conditions was more successful in the NSCLC brain metastasis group. We had attempted to make tumor spheres in vitro using 15 and 25 PDX tumors from primary and brain metastatic tumors, respectively. In 1 (1/15, 6.6%) and 9 (9/25, 36%) cases, tumors sphere was formed (P ¼ 0.038). Among the 9 brain metastasis cases, 5 cases showed in vitro passagability (P > 3). In the other cases (n ¼ 4), we confirmed tumor sphere formation in the second in vitro passage, whereas further subculture was not tried. These data indicated that PDX models using surgical samples of NSCLC brain metastases could be better suited as the preclinical platform for NSCLC in terms of technical feasibility and unmet clinical needs. Accordingly, we further validated the applicability of NSCLC brain metastasis PDX models for preclinical screening of personalized anticancer therapeutics using five representative cases, LC-MBT-15, LC-MBT-17, LC-MBT-19, LC-MBT-33, and LC-MBT-34 ( Fig. 2A and Supplementary Table S4 ). LC-MBT-15 was a metachronous brain metastasis obtained from a 56-year-old woman with a smoking history and confirmed lung adenocarcinoma diagnosis with extracranial lung, liver, and bone metastases. This patient experienced treatment resistance to multiple chemotherapy regimens including erlotinib, an agent targeting EGFR. LC-MBT-17 was a metachronous brain metastasis of a 68-year-old man with a smoking history and confirmed lung SCC diagnosis. Erlotinib also showed no clinical benefit in this case. LC-MBT-19 was a 65-year-old female nonsmoker who initially presented with a mass in the left upper lobe (adenocarcinoma) and a synchronous brain metastasis. No extracranial metastases were identified via imaging studies, including PET-CT. This patient did not receive any treatment before surgical resection. LC-MBT-33 was a 68-year old male smoker who was initially diagnosed as a lung SCC. During clinical managements, this patient experienced chemoresistance and a brain metastasis. LC-MBT-34 was a metachronous brain metastasis of a 68-year-old male with a smoking history. This patient with lung SCC had chemotherapy, which did not show significant clinical efficacy to draw multiple systemic metastases, including brain, bone, liver, and adrenal gland. When genomic alterations of EGFR, ALK, and KRAS were examined for these cases, a duplication of EGFR exon 20 and a KRAS mutation (12G>C) was found in LC-MBT-15 and LC-MBT-34, respectively (Supplementary Table S4 ).
PDX models were successfully established from the surgical samples of the five cases. NSCLC cancer cells were primarily cultured in serum-free condition from the five PDX tumors, demonstrating in vitro sphere-forming capacity (Fig. 2B) . Furthermore, when 1 Â 10 4 primarily cultured LC-MBT-15, LC-MBT-17, or LC-MBT-19 cancer cells were injected into the left ventricle of nude mice, systemic metastatic tumors were formed in various organs including the brain (Fig. 2B) to effectively confirm the in vivo brain metastatic potential. However, correlation between extracranial metastatic sites of parental tumors and corresponding animal models was not observed (Fig. 2A) . The genetic properties of patients' surgical samples, PDX tumor tissues, and dissociated PDX tumor cells were analyzed by aCGH and the Ion Personal Genome Machine Sequencer using the Ion AmpliSeq Cancer Panel (22) . EGFR exon-20 duplication was consistently detected in LC-MBT-15 (Fig. 2C) . LC-MBT-17, LC-MBT-19, LC-MBT-33, and LC-MBT-34 harbored ERBB4 (1058T>A), TP53 (839G>C), KRAS (12G>A), and TP53 (1015T>C) mutations, respectively (Fig. 2C) . No other genetic mutations were detected. The genetic mutations and copy-number variations of patients' tumors were preserved in both xenografts and primarily cultured cancer cells in all five cases (Fig. 2C  and D) .
The IC 50 values for 20 targeted agents were obtained in vitro using the primarily cultured cells in sphere culture condition ( Table 3 ). The drug library was composed of targeted agents included in the clinical guideline or current clinical trials for the treatment of NSCLC. Cells were considered resistant to an agent when the IC 50 of that agent was greater than 1,000 nmol/L, according to the previous studies (23) . Interestingly, the efficacy of these 20 therapeutic agents varied dramatically in five cases examined (>100-fold differences in IC 50 , Table 3 ), indicating the possibility of personalized approach.
Elucidation of case-specific oncogenic signaling using NSCLC brain metastasis PDX models
As shown in Table 3 , the proliferation of LC-MBT-15 cells was not affected by EGFR inhibitors such as gefitinib (IC 50 ¼ 7,900 nmol/L), erlotinib (IC 50 > 20,000 nmol/L), and lapatinib (IC 50 ¼ 4,100 nmol/L). Only afatinib, an irreversible EGFR and HER2 inhibitor, showed marked inhibitory effects on LC-MBT-015 cell proliferation (IC 50 ¼ 270 nmol/L, Table 3 ). Patients with NSCLC with EGFR mutations in exons 18, 19, or 21, which encompass most of the tyrosine kinase domain of EGFR (24), have been shown to respond to EGFR-targeted agents including erlotinib (25, 26) . However, EGFR in-frame duplication and/or insertion mutations in exon 20 (27) often result in poorer responsiveness to these EGFR inhibitors (28) . The resistance to erlotinib of LC-MBT-15 cells was consistent with the clinical treatment outcomes of this patient whose tumors harbored EGFR exon-20 duplication mutation ( Fig. 2A) . However, afatinib reportedly exhibits therapeutic effects on patients with NSCLC with EGFR exon-20 duplication (insertion) mutations (29) , which was reproduced in vitro in this study. In addition, tivantinib, an MET-targeted agent, showed a similar IC 50 (270 nmol/L) for the proliferation of LC-MBT-15 cells to that of afatinib. Interestingly, the sensitivity was correlated with decreased phosphorylation of ERK regardless of the primary therapeutic targets (Fig. 3A) , suggesting the downstream ERK signaling pathway is important in the proliferation of LC-MBT-15 cells. Accordingly, an ERK inhibitor, SCH772984, significantly reduced ERK phosphorylation of LC-MBT15 cells and showed inhibitory effects on proliferation (Fig. 3B) .
LC-MBT-19, an adenocarcinoma with wild-type EGFR, showed better response to EGFR-targeted therapeutics (gefitinib, erlotinib, lapatinib, and afatinib) than LC-MBT-15 (Table 3) . Treatment with EGFR-targeted agents reduced the phosphorylation of EGFR; however, AKT phosphorylation, a downstream signaling component of EGFR, was decreased by only afatinib, which showed the lowest IC 50 for the proliferation of LC-MBT-19 cells (Table 3 and Fig. 3C ). Although EGFR wild-type adenocarcinomas have been reported to be resistant to EGFR-targeted agents clinically, afatinib had therapeutic activities against this patient population (30, 31), which could draw the lowest IC 50 . Interestingly, the activation status of ERK was not affected by any of the EGFRtargeted agents. Crizotinib, a specific inhibitor of ALK and MET, dramatically suppressed the phosphorylation of MET but not AKT, and had a relatively high IC 50 (3,100 nmol/L). Accordingly, the proliferation of LC-MBT-19 cells was decreased by an AKT inhibitor, AZD5363, which significantly reduced the phosphorylation of AKT downstream signaling components, such as GSK3b and PRAS (Fig. 3B) . These results indicated that AKT signaling pathway rather than ERK is important for LC-MBT-19 cell survival and proliferation.
The proliferation of LC-MBT-17, a case of SCC, cells was not affected by EGFR and MET inhibitors (Table 3) , while mTOR inhibitors (temsirolimus and everolimus) showed low IC 50 values (43 and 65 nmol/L, respectively) by totally abolishing the phosphorylation of p70S6K, a downstream signaling component of mTOR (Fig. 3B) . In contrast, erlotinib effectively suppressed the phosphorylation of both AKT and ERK (Fig. 3B ), but could not suppress the proliferation of LC-MBT-17 cells. Therefore, the mTOR-p70S6K pathway, rather than the AKT and ERK pathways, was thought to be important in the proliferation of LC-MBT-17 cells. Another SCC case, LC-MBT-33, showed differential sensitivity to MET inhibitors (tivantinib, foretinib, and crizotinib; IC 50 ¼ 260, 260, and 930 nmol/L, respectively), whereas LC-MBT-34 SCC cells did not respond to most of tested agents except temsirolimus (Table 3) .
Discussion
The morbidity of NSCLC brain metastasis is rising, and the prognosis of patients remains poor with a median survival of only a few weeks to months despite intensive multimodal therapy (32) . Nevertheless, very few pathophysiologic studies have been performed on NSCLC brain metastasis, and the appropriate preclinical models for such studies remain to be defined. Since the 1980s, surgery has become a standard therapeutic option for (12) . Moreover, surgical resection could improve both patients' survival and quality of life (33, 34) . Therefore, surgically obtained NSCLC brain metastasis samples could be utilized to establish NSCLC PDXs without ethical issues. In this study, NSCLC brain metastasis samples demonstrated high engraftment efficiency in immune-deficient mice (74%), and the resulting PDXs closely resembled the original tumors morphologically and molecularly. In addition, they recapitulated the corresponding patients' functional characteristics such as in vivo brain metastatic potential and differential drug responses, indicating their potential as in vitro and in vivo preclinical models for advanced NSCLCs.
Preclinical drug development has traditionally relied on established human cancer cell lines that are cultured in serum-containing media in adherent conditions for extended periods of time. However, the reliability of such cell lines has provoked considerable debates due to the high failure rate of newly developed targeted agents in subsequent clinical trials (35) . Xenografts derived from cell lines generally show a homogeneous histology with a lack of human stroma and immune cells, which are important for tumor growth and metastatic processes (36) . In contrast, xenografts directly derived from patient biopsies or surgical specimens with minimal in vitro manipulations appear to possess better retention of the morphologic and molecular characteristics of the original tumors (37) . Therefore, PDXs may be an informative preclinical model for the development of novel therapeutics as they can more accurately predict the subsequent clinical success and allow various mechanistic studies that are not possible in patients (37) .
The elucidation of target populations is a prerequisite for the clinical success of molecularly targeted agents. Because of the limited intra-and intertumoral heterogeneity of conventional cell lines, it is very difficult to develop reliable personalized strategies in the preclinical stage. Combining PDXs with high-throughput drug screening technologies would be a promising solution, because PDXs recapitulate the functional properties of corresponding individual tumors and a PDX library would represent heterogeneous patient populations. Indeed, drug screening experiments in this study using five independent NSCLC brain metastasis samples showed dramatically different responses to targeted agents, highlighting the importance of personalized approaches. Although several drug screening tests have been performed on resected NSCLC specimens, including in vitro tests using short-term cell cultures (38) and in vivo tests using firstgeneration tissue xenografts in immune-deficient mice (39) , early attempts to use primary lung tumors as experimental models had limited success. In particular, primary NSCLC-derived PDXs showed low in vivo take rate (30%-40%), which is similar to our results (23%; refs. 7, 10). While specific factors associated with successful in vivo engraftment of primary lung tumors, such as squamous histology, the presence of distant metastasis, solid growth pattern, and wild-type EGFR genotype, were elucidated by this and previous studies (10, 16, 40) , those factors would inevitably limit applicable NSCLC patient populations. In contrast, no significant factor was found in cases of NSCLC brain metastases. In spite of those merits of using surgical samples of NSCLC brain metastasis, their availability would limit the experimental and/or clinical applications of them because surgical managements are not usually primary medical treatments for patients with NSCLC brain metastasis.
The fact that preclinical drug sensitivity data are obtained from primary NSCLC models instead of systemic metastatic advanced NSCLC models could be another reason for the mismatch between preclinical and clinical treatment results (10) . Indeed, aCGH analyses or single nucleotide polymorphism arrays utilizing primary and paired metastasis tissues showed considerable discrepancies (41, 42) . Furthermore, functional analyses revealed significant differences in the proliferation, motility, and chemosensitivity of cancer cells (43) . Especially, chemosensitivity is strongly affected by the biologic aggressiveness of tumor cells, such as the metastatic potential (39, 44, 45) . Therefore, concerted efforts to utilize surgical samples obtained from advanced cases are necessary to represent clinical situations with more treatmentresistant or metastatic diseases. The significant association between PDX formation capacity and clinical aggressiveness of the parental NSCLCs (16, 40) has important preclinical and clinical implications. In this study, as NSCLC brain metastasis samples were efficiently engrafted in vivo, and established PDXs recapitulated the histopathologic, genomic, and biologic properties of parental NSCLCs in situ, our strategy of using surgically resected metastatic tissues would provide more reliable translational models representing the aggressive phenotypes and genotypes of NSCLC for rationale-driven clinical trials to overcome NSCLC treatment resistance or metastasis.
Recent attention has focused on the need for better models that preserve the integrity of cancer stem cell (CSC) populations. Many studies have reported the increased invasiveness of CSCs, implicating the involvement of CSCs in the progression and/or development of metastases (46, 47) . However, most previous in vitro drug screenings on lung cancer patient-derived cancer cells were performed in serum-containing medium (48) , whereas tumor spheres in serum-free condition enrich CSC-like populations (49) . Herein, PDXs derived from NSCLC brain metastases gave rise to numerous tumor spheres in a few days after mechanical dissociation ex vivo in a reproducible manner, whereas PDXs from NSCLC primary tumor demonstrated poor viability and sphereforming ability in vitro. In previous study, the ability to form tumor spheres was also correlated with tumor aggressiveness, and the chemosensitivity of tumor spheres was similar to that of the in vivo original xenografts (50) . Therefore, ex vivo tumor spheres would be one of the potential preclinical tools for the validation of new drugs in a setting that more closely resembles patients' tumors but also for the investigation of patient-tailored therapeutics with high-throughput drug screen.
In this study, we demonstrated that brain metastases from NSCLC could be a valuable resource for the establishment of PDXs as a powerful preclinical platform to further develop personalized approaches for the treatment of patients with advanced NSCLC. Moreover, a platform library representing heterogeneous advanced NSCLCs would be a valuable modality for the comprehensive understanding of NSCLC progression and metastasis as well as mechanisms of drug resistance.
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